Subtopic Deep Dive
PARP Trapping and DNA Damage
Research Guide
What is PARP Trapping and DNA Damage?
PARP trapping refers to the stabilization of PARP enzymes on DNA by clinical PARP inhibitors (PARPi), forming cytotoxic PARP-DNA complexes that induce DNA double-strand breaks distinct from catalytic PARP inhibition.
PARP trapping emerged as the primary mechanism of PARPi cytotoxicity in BRCA-deficient cancers, surpassing enzymatic inhibition (Murai et al., 2012, 2093 citations). This process traps PARP1 and PARP2 at DNA single-strand breaks, leading to replication fork collapse and cell death. Over 10 key papers since 2005 have established its role in synthetic lethality.
Why It Matters
PARP trapping explains differential potency among clinical PARPi like olaparib and niraparib, guiding structure-activity optimization for enhanced cancer therapy (Murai et al., 2012). It underpins synthetic lethality in BRCA-mutant tumors, enabling tumor-specific killing with reduced effects on normal cells (Farmer et al., 2005; Bryant et al., 2005). Clinical trials validate trapping-driven efficacy in ovarian, prostate, and pancreatic cancers (Fong et al., 2009; Moore et al., 2018; de Bono et al., 2020). Insights into trapping inform resistance mechanisms and combination therapies.
Key Research Challenges
Quantifying Trapping Potency
Distinguishing trapping from catalytic inhibition requires precise assays measuring PARP-DNA complex stability. Murai et al. (2012) developed methods showing veliparib's weak trapping despite strong inhibition. Challenge persists in predicting clinical activity from in vitro data.
Replication Fork Protection
PARPi protect stalled forks in normal cells but collapse them in HR-deficient cells, complicating toxicity profiles. Lord and Ashworth (2017) highlight fork protection as a resistance factor. Balancing cytotoxicity and off-target fork instability remains unresolved.
Off-Target Effects
Clinical PARPi exhibit unintended DNA interactions beyond PARP trapping, affecting non-BRCA tumors. Garnett et al. (2012) identified genomic markers of sensitivity via systematic screening. Defining trapping-specific versus broad DNA damage signatures hinders selective therapy.
Essential Papers
Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy
Hannah Farmer, Nuala McCabe, Christopher J. Lord et al. · 2005 · Nature · 6.5K citations
Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase
Helen E. Bryant, Niklas Schultz, Huw D. Thomas et al. · 2005 · Nature · 5.0K citations
Inhibition of Poly(ADP-Ribose) Polymerase in Tumors from <i>BRCA</i> Mutation Carriers
Peter C.C. Fong, David S. Boss, Timothy A. Yap et al. · 2009 · New England Journal of Medicine · 3.6K citations
Olaparib has few of the adverse effects of conventional chemotherapy, inhibits PARP, and has antitumor activity in cancer associated with the BRCA1 or BRCA2 mutation. (ClinicalTrials.gov number, NC...
Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer
Kathleen N. Moore, Nicoletta Colombo, Giovanni Scambia et al. · 2018 · New England Journal of Medicine · 2.7K citations
The use of maintenance therapy with olaparib provided a substantial benefit with regard to progression-free survival among women with newly diagnosed advanced ovarian cancer and a BRCA1/2 mutation,...
PARP inhibitors: Synthetic lethality in the clinic
Christopher J. Lord, Alan Ashworth · 2017 · Science · 2.7K citations
PARP inhibitors (PARPi), a cancer therapy targeting poly(ADP-ribose) polymerase, are the first clinically approved drugs designed to exploit synthetic lethality, a genetic concept proposed nearly a...
Systematic identification of genomic markers of drug sensitivity in cancer cells
Mathew J. Garnett, Elena J. Edelman, Sonja J. Heidorn et al. · 2012 · Nature · 2.5K citations
Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer
Mansoor R. Mirza, Bradley J. Monk, Jørn Herrstedt et al. · 2016 · New England Journal of Medicine · 2.4K citations
Among patients with platinum-sensitive, recurrent ovarian cancer, the median duration of progression-free survival was significantly longer among those receiving niraparib than among those receivin...
Reading Guide
Foundational Papers
Start with Farmer et al. (2005, 6496 citations) and Bryant et al. (2005, 5038 citations) for synthetic lethality discovery, then Murai et al. (2012, 2093 citations) for trapping mechanism establishing cytotoxicity dominance.
Recent Advances
Study Lord and Ashworth (2017, 2681 citations) for clinical translation and fork protection; Moore et al. (2018, 2683 citations) and de Bono et al. (2020, 2114 citations) for trial outcomes linking trapping to PFS benefits.
Core Methods
Core techniques: alkaline comet assays for trapping (Murai et al., 2012); CRISPR screens for sensitivity markers (Garnett et al., 2012); clinical response via ctDNA in BRCA mutants (Fong et al., 2009).
How PapersFlow Helps You Research PARP Trapping and DNA Damage
Discover & Search
Research Agent uses citationGraph on Farmer et al. (2005) to map 6,496-cited synthetic lethality papers to Murai et al. (2012) trapping mechanism, then exaSearch for 'PARP trapping SAR clinical PARPi' to uncover 50+ structure-activity studies. findSimilarPapers on Murai et al. reveals fork protection papers like Lord and Ashworth (2017).
Analyze & Verify
Analysis Agent applies readPaperContent to Murai et al. (2012) abstract confirming trapping as primary cytotoxicity, then verifyResponse (CoVe) cross-checks claims against Farmer et al. (2005) and Bryant et al. (2005). runPythonAnalysis plots IC50 vs. trapping efficiency from Garnett et al. (2012) datasets with GRADE scoring for evidence strength in BRCA models.
Synthesize & Write
Synthesis Agent detects gaps in trapping vs. catalytic inhibition debates across Fong et al. (2009) clinical data, flagging contradictions with exportMermaid for mechanism diagrams. Writing Agent uses latexEditText to draft SAR tables, latexSyncCitations for 10+ papers, and latexCompile for publication-ready reviews.
Use Cases
"Extract trapping potency data from Murai 2012 and plot vs clinical efficacy"
Research Agent → searchPapers 'Murai PARP trapping' → Analysis Agent → readPaperContent + runPythonAnalysis (pandas/matplotlib IC50 curves) → GRADE verification → researcher gets plotted potency-efficacy correlation CSV.
"Write LaTeX review on PARP trapping in ovarian cancer trials"
Synthesis Agent → gap detection (Moore 2018, Mirza 2016) → Writing Agent → latexGenerateFigure (trapping mechanism) → latexSyncCitations (Fong 2009 et al.) → latexCompile → researcher gets compiled PDF with diagrams and synced refs.
"Find code for PARP inhibitor sensitivity screening"
Research Agent → searchPapers 'Garnett 2012 genomic markers' → Code Discovery → paperExtractUrls → paperFindGithubRepo → githubRepoInspect → researcher gets validated GitHub repo with drug sensitivity analysis scripts.
Automated Workflows
Deep Research workflow scans 50+ papers from Farmer (2005) citations via citationGraph, structures trapping mechanisms report with CoVe checkpoints. DeepScan's 7-step analysis verifies Murai (2012) trapping data against clinical trials (Moore 2018). Theorizer generates hypotheses on trapping-resistant fork protection from Lord-Ashworth (2017).
Frequently Asked Questions
What defines PARP trapping?
PARP trapping is the drug-induced stabilization of PARP1/2 on DNA ends, forming lethal complexes that cause replication fork collapse (Murai et al., 2012).
How does trapping differ from catalytic inhibition?
Catalytic inhibition blocks PARP enzymatic activity for NAD+ conservation; trapping physically immobilizes PARP on DNA, amplifying cytotoxicity 1000-fold in HR-deficient cells (Murai et al., 2012).
What are key papers on PARP trapping?
Foundational: Murai et al. (2012, 2093 citations) established trapping mechanism; Farmer et al. (2005, 6496 citations) and Bryant et al. (2005, 5038 citations) introduced synthetic lethality.
What open problems exist in PARP trapping research?
Challenges include predicting clinical trapping potency from preclinical assays, understanding fork protection resistance, and minimizing off-target DNA damage (Lord and Ashworth, 2017; Garnett et al., 2012).
Research PARP inhibition in cancer therapy with AI
PapersFlow provides specialized AI tools for Medicine researchers. Here are the most relevant for this topic:
Systematic Review
AI-powered evidence synthesis with documented search strategies
AI Literature Review
Automate paper discovery and synthesis across 474M+ papers
Find Disagreement
Discover conflicting findings and counter-evidence
Paper Summarizer
Get structured summaries of any paper in seconds
See how researchers in Health & Medicine use PapersFlow
Field-specific workflows, example queries, and use cases.
Start Researching PARP Trapping and DNA Damage with AI
Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.
See how PapersFlow works for Medicine researchers
Part of the PARP inhibition in cancer therapy Research Guide